Probiotics: does a higher CFU count mean a better effect?

Ten, fifty or a hundred billion: on a probiotic package, a bigger number easily looks like a promise of quality. Yet the count of colony-forming units describes only one part of the product. Whether it might help depends on the exact microorganism, the use it was studied for, its shelf stability and the formulation that was actually tested. More microbes do not automatically mean more effect.

What CFU measures, and what it does not

CFU stands for “colony-forming units” (in German, koloniebildende Einheiten or KBE). The count shows how many units can form colonies under defined laboratory conditions. One such unit can also arise from a cluster of cells, so the number is not always identical to the number of individual living cells. Probiotics may also contain yeasts as well as bacteria.

What matters most is when the count applies. Some manufacturers state the count at the time of manufacture, while others guarantee it until the end of shelf life under the specified storage conditions. Heat, moisture and oxygen can reduce viability. A product with a higher nominal dose that has been stored poorly can therefore contain fewer organisms able to multiply than a lower-dose product that has been stored correctly.

The CFU figure measures neither activity in the human gut nor survival in stomach acid and bile. Nor does it say anything reliable about adhesion to the gut lining, how long the microbes stay, or any clinical benefit. In particular, permanent colonization is not required for every probiotic effect.

What clinical data say about dose

Studies use, among other amounts, between one and ten billion CFU per day. That range is not a universal standard dose: depending on strain, formulation, age and goal, the amounts studied can differ considerably. Effective uses cannot be reliably confined to exactly this range.

Lacticaseibacillus rhamnosus GG, formerly Lactobacillus rhamnosus GG, has for example been studied in antibiotic-associated diarrhea. An effect seen at one amount cannot simply be multiplied up to predict what five times as many CFU would do. Nor can a higher dose of a different strain be treated as equivalent.

Very high amounts have also been studied in intensive care. Those studies are precisely not a reason for seriously ill people to treat themselves: a damaged gut barrier and weakened immune defenses can increase the risks. Benefit and safety have to be assessed separately for each specific population.

How digestion changes the amount that arrives

Stomach acid and bile salts are a stress for many microorganisms. Experiments in simulated gastric fluid describe losses of 90 to 99 percent within 30 minutes under strongly acidic conditions. Such lab figures should not be presented as a universal loss rate after every capsule. Meals, gastric emptying, the strain and the product change the conditions considerably.

Some strains tolerate acid or bile better than others. Technical methods can add protection: enteric coatings, delayed release and microencapsulation, for example with alginate. A protected product with a lower dose could therefore deliver more viable organisms to later sections of the gut than an unprotected product with a higher dose. But that becomes a proven clinical advantage only once the formulation in question has actually been studied.

Saying that only arrival in the colon counts would also be too narrow. Some effects may arise along the way or through brief contact. “Survives digestion” and “helps with my symptom” are different questions.

Why the exact strain name matters

Probiotics are classified by genus, species and strain. Two members of the same species can differ in their metabolism, surface structures and clinical effects. A label that says only “Lactobacillus”, or gives only the species, does not allow a reliable match with a study.

Different immunological mechanisms have been described for L. rhamnosus GG and Bifidobacterium longum BB536. Such mechanisms cannot be turned into a general ranking. What matters is whether the specific strain has been studied for the specific goal in a comparable group of people.

LGG is a common shorthand for the GG strain. A different spelling alone does not make it two microorganisms. Naming questions like this one show why a sound product comparison needs more than a high microbe count.

Dose, form, timing and storage

Dose

A suitable study of the strain combination actually in the product gives you a reference point. A dose of one to ten billion CFU is not automatically enough, and 50 to 100 billion is not automatically better. In a blend, it should also be clear which strains are present and in what amounts. A large total can hide small amounts of the clinically relevant component.

Form

Capsule technology, the powder matrix and stability data can matter for viability. Terms such as “enteric-coated” should not, however, stand in for clinical data. A sturdy product with plausible stability still does nothing for a goal its strain has no proven benefit for.

Timing

Meals can buffer stomach acid and provide a protective matrix. The 2022 publication does not provide a sufficient basis for a universal rule to take probiotics “with fat” or “on an empty stomach”. Studies on survival during digestion also need to be kept separate from clinical benefit. What counts is the use that was tested and the instructions for the specific product.

Storage

Products that require refrigeration must be kept cold. Others are stable at room temperature thanks to freeze-drying and suitable packaging. Not every probiotic needs a fridge. What matters are the limits stated explicitly, the best-before date, and protection from heat and moisture. A high starting count cannot reliably make up for poor storage.

Who might benefit from higher amounts, and where caution is needed

The existing gut ecosystem, medications and illnesses can all influence the response. That does not, however, yield a simple rule such as “low diversity equals high dose”. A short course of antibiotics is a different context from chronic inflammatory bowel disease, chemotherapy or intensive care.

In severe illness, immunosuppression, with a central catheter or with a marked barrier disorder, live microorganisms can be a problem. Their use belongs with the treating facility and should not be derived from a general guide.

For children, age, strain and indication are decisive; a blanket adult or child dose is not appropriate. In older people, too, acid production, medications and disease burden change in different ways. Acid blockers can affect conditions in the stomach, but they do not predict which probiotic will work.

What a microbiome test can add to the choice

Stool tests can describe the composition detectable in the sample. Species richness, Shannon diversity or relative abundances are not, however, universal target values for individual treatment. A low relative amount of one genus does not prove a deficiency that has to be fixed with the same genus from a capsule.

Figures for “butyrate, propionate and acetate capacity” may be potentials inferred from genetic or taxonomic data. They are not automatically direct measurements of how much the body produces. Results also depend on the method, the sample and fluctuations over time.

A change after eight to twelve weeks therefore does not, on its own, show that a supplement helps clinically. Conversely, an unchanged stool test does not prove that there is no symptomatic effect at all. A commercial microbiome test is not a general prerequisite for a sensible decision about probiotics.

Making a product choice you can explain

Start with a clear goal: for example, a specific diarrhea situation assessed by a doctor rather than vague “gut optimization”. Then you can compare the strain, formulation, studied amount and duration. A full strain name, a count guaranteed through shelf life and suitable storage are useful quality markers. Buying without a goal, simply by the biggest number of billions, tells you less.

To track progress, note your symptoms, stool frequency, tolerability and anything else that changed at the same time. Persistent diarrhea, blood in the stool, fever, weight loss or dehydration should be checked by a doctor. They are not a reason simply to try more CFU.

Frequently asked questions

What does CFU on the label mean?

It refers to colony-forming units under laboratory conditions. The key question is whether the number applies at the time of manufacture or until the end of shelf life. It does not describe a guaranteed health effect.

Why are one to ten billion so often studied?

Amounts of this order appear in a range of study protocols. That does not create a universal optimal range. The effective amount has to fit the particular strain combination and use.

How much survives the stomach?

There is no general answer without data for the specific product. Lab losses of 90 to 99 percent cannot be transferred to every real-world dose.

Why is the strain more important than the total count?

Different strains can have different effects even at the same microbe count. Only a full strain name allows a match with the research; GG and LGG are common names for the same strain.

Should probiotics be taken with food?

A meal may suit some formulations. No general rule for all bacteria, yeasts and capsules follows from that. The use tested for the specific product is the best guide.

Do healthy people need high-dose products?

A general added benefit has not been shown. A stable digestive system does not need to be altered with as many extra microbes as possible.

How important is storage?

Very important for viability. Refrigeration is needed when the label says so; for room-temperature-stable products, the manufacturer’s stated limits apply. Avoid heat and moisture.

What should I look for besides CFU?

The exact strains, matching clinical data, a count guaranteed through shelf life, storage and formulation. Tolerability and personal risk factors belong on the list too.